Pipeline

Program Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Etrasimod (APD334)
Optimized Activity S1P Receptor Modulator
 
Ulcerative Colitis (UC)

50%

Arena: Worldwide
Ralinepag (APD811)
Prostacyclin (IP) Receptor Agonist

 
Pulmonary Arterial Hypertension (PAH)

50%

Arena: Worldwide
APD371
Highly Selective Full Agonist to CB2
 
Crohn’s Pain

41%

Arena: Worldwide
Partnered Programs
BELVIQ and BELVIQ XR
 
Weight Loss Approved: CVOT Ongoing

98%

Eisai: Most of World
Ildong: South Korea
CYB: Taiwan
Teva: Israel
Nelotanserin
5-HT2A Inverse Agonist
 
Dementia Associated Psychosis

50%

Axovant: Worldwide
Undisclosed Orphan GPCR
 
CNS

15%

Boehringer Ingelheim: Worldwide

Program Indication Phase Commercial Rights
Internal Programs
Etrasimod (APD334)
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) Ph2 Arena:
Worldwide
Ralinepag (APD811) Prostacyclin (IP) Receptor Agonist
Pulmonary Arterial Hypertension (PAH) Ph2 Arena:
Worldwide
APD371 Highly Selective Full Agonist to CB2
Crohn’s Pain Ph1 Arena:
Worldwide
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing Market Eisai: Most of World Ildong: South Korea CYB: Taiwan Teva: Israel
Nelotanserin 5-HT2A Inverse Agonist
Dementia Associated Psychosis Ph2 Axovant:
Worldwide
Undisclosed Orphan GPCR
CNS Pre-Clin Boehringer Ingelheim:
Worldwide
 Clinical Trial  Publications